-
Views
-
Cite
Cite
Shelley F. Stone, Patricia Price, Jean Brochier, Martyn A. French, Plasma Bioavailable Interleukin-6 Is Elevated in Human Immunodeficiency Virus–Infected Patients Who Experience Herpesvirus-Associated Immune Restoration Disease after Start of Highly Active Antiretroviral Therapy, The Journal of Infectious Diseases, Volume 184, Issue 8, 15 October 2001, Pages 1073–1077, https://doi.org/10.1086/323599
- Share Icon Share
Abstract
This study compared plasma bioavailable interleukin (IL)–6 levels in 3 groups: human immunodeficiency virus (HIV)–infected patients who had a human herpesvirus (HHV)–associated immune restoration disease (IRD) during highly active antiretroviral therapy (HAART); patients who experienced an IRD initiated by Mycobacterium avium complex, hepatitis C virus, or human papillomavirus; and control patients who had uneventful immune reconstitution. Total IL-6, soluble IL-6 receptor (sIL-6R), and soluble gp130 were measured by ELISA, and levels of free IL-6 and sIL-6/IL-6R complex were modeled mathematically. Persons who had an HHV-associated IRD had increased plasma bioavailable IL-6 before HAART, compared with patients who experienced a non–HHV-associated IRD and with control patients, and their plasma bioavailable IL-6 increased progressively over 3–4 years of treatment. Increased IL-6 production may be a feature of HAART-induced restoration of immune responses to HHV infections and may have long-term immunopathologic consequences
- hiv
- herpesviridae
- simplexvirus
- enzyme-linked immunosorbent assay
- immune response
- antiretroviral therapy, highly active
- human papillomavirus
- interleukins
- plasma
- interleukin 6 receptor
- interleukin-6
- hepatitis c virus
- immune reconstitution inflammatory syndrome
- squamous intraepithelial lesions
- pmel17
- immune reconstitution